Skin Cancer

Precision medicine may help improve the diagnosis and management of this aggressive skin cancer.

At the 2022 Fall Clinical Dermatology Conference, a dermatologist shares results of using cemiplimab-rwlc (Libtayo) for basal and squamous cell carcinoma.

At a session at the 2022 Fall Clinical Dermatology Conference, 2 clinicians discuss some of the top testing methods for skin cancer.

At the Melanoma Update of the Annual ASDS Meeting, Tyler Hollmig, MD, looked at complex clinical scenarios when treating melanoma and the continued challenges dermatologists face.

Kimberly Ken, MD, assistant professor of dermatology at Penn State University, discussed crucial methods for advanced melanoma management.

Authors of an oral abstract at the 2022 ASDS Annual Meeting presented their findings on the demographics of who requests total body skin exams to screen for skin cancer.

Sherrif F. Ibrahim, MD, PhD, and Vishal Patel, MD, FAAD, FACMS, provide initial impressions of the case and discuss the use of immune checkpoint inhibitors.

Sherrif F. Ibrahim, MD, PhD, presents the case of a 49-year-old White woman with neglected large basal cell carcinoma.

Expert dermatologists discuss future directions for the management of basal cell carcinoma.

Sherrif F. Ibrahim, MD, PhD, and Vishal Patel, MD, FAAD, FACMS, discuss the impact of immune checkpoint inhibitors used in BCC.